The global liquid biopsy market was valued at USD 9.63 billion in 2024 and is expected to grow from USD 11.66 billion in 2025 to USD 58.64 billion by 2032, registering a CAGR of 25.9% during the forecast period. In 2024, North America led the global liquid biopsy market, accounting for a 54.43% share.

The liquid biopsy market is emerging as a transformative tool in cancer diagnostics and monitoring. It enables the detection of tumor-derived materials such as circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) through a non-invasive blood draw. This technology offers significant advantages over traditional tissue biopsies, including real-time disease tracking, early detection, and treatment response assessment. Growing demand for personalized medicine, increasing cancer prevalence, and advancements in next-generation sequencing technologies are key factors driving the expansion of the global liquid biopsy market.

Tariff Impact Analysis for Liquid Biopsy Market:

**https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506**

Market Segmentation:

• The liquid biopsy market can be segmented based on biomarker type, application, cancer type, and end-user:
• By Biomarker Type: The market includes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNA, and exosomes.
• By Application: Key applications include early cancer detection, treatment monitoring, recurrence detection, and companion diagnostics.
• By Cancer Type: The market addresses various cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and others.
• By End-User: Major end-users include hospitals, diagnostic laboratories, academic research centers, and biotechnology companies.

Key Companies Featured in the Liquid Biopsy Market Report:

• Guardant Health (U.S.)
• PERSONALIS, INC. (U.S.)
• FOUNDATION MEDICINE, INC. (U.S.)
• Natera, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)
• Menarini Silicon Biosystems, Inc. (Italy)
• Thermo Fisher Scientific Inc. (U.S.)